Drug profile · INN
insulin degludec + insulin aspart
RYZODEG PENFILL
insulin degludec + insulin aspart (RYZODEG PENFILL) is an FDA-listed pharmaceutical active ingredient. Associated with NovoThirteen.
TGA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — insulin degludec + insulin aspart
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
insulin degludec + insulin aspart (RYZODEG PENFILL) is an FDA-listed pharmaceutical active ingredient. Associated with NovoThirteen.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Frequently asked questions
What is insulin degludec + insulin aspart?
insulin degludec + insulin aspart (RYZODEG PENFILL) is an FDA-listed pharmaceutical active ingredient. Associated with NovoThirteen.
What is the brand name for insulin degludec + insulin aspart?
RYZODEG PENFILL is a marketed brand name for insulin degludec + insulin aspart. Check FDA Drugs@FDA for the current US label holder and prescribing information.